Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

A person holding an insulin pen for an article about California low-cost insulin program

California launches its own low-cost insulin program at 1 per pen

By / / Good News For Humankind

California’s low-cost insulin program marks a historic first in American healthcare. Starting January 1, 2026, California will sell state-branded insulin pens for just 1 each through its CalRx program, undercutting pharmaceutical prices that can run four to seven times higher. The state partnered with nonprofit manufacturer Civica Rx to produce the biosimilar medication, bypassing the market forces that have made insulin unaffordable for millions. With over 38 million Americans living with diabetes, this publicly backed manufacturing model could offer a replicable blueprint for addressing runaway prescription drug costs nationwide.

Colorized microscopy image of neurons and plaques for an article about Alzheimer's nanoparticle treatment

A single injection reversed Alzheimer’s symptoms in mice, and researchers say humans could be next

By / / Good News For Humankind

Alzheimer’s nanoparticle treatment developed by scientists in Spain and China reversed disease symptoms in mice with a single injection, according to a study published in Nature Nanotechnology. Rather than targeting amyloid-beta plaques directly, the engineered nanoparticles crossed the damaged blood-brain barrier and restored the brain’s own waste-clearance system. Within one hour, researchers recorded a sharp drop in toxic protein levels, with memory function fully restored and effects lasting the equivalent of decades in human terms. While mouse results don’t guarantee human outcomes, the mechanism targeting barrier function over individual markers may prove more durable than previous approaches.

Health workers preparing oral vaccines in a field setting for an article about cholera vaccination campaign in Darfur

Cholera vaccination campaign reaches 1.86 million people in Darfur amid active conflict

By / / Good News For Humankind

Sudan cholera vaccination campaign: In late September 2025, health workers delivered oral cholera vaccines to more than 1.86 million people across six localities in the Darfur states, navigating active conflict, broken infrastructure, and collapsed supply chains to reach nearly 97% of the targeted population. Coordinated by Sudan’s Ministry of Health with WHO, UNICEF, and global partners, the campaign addressed an outbreak spanning all 18 states, with over 113,000 cases and 3,000 deaths recorded since July 2024. Beyond vaccination, teams trained local health workers and delivered hygiene education, building lasting community capacity.

A neuroscientist reviewing brain scan imagery for an article about Huntington's disease gene therapy

U.K. scientists slow Huntington’s disease progression for the first time

By / / Good News For Humankind

Huntington’s disease gene therapy has achieved what researchers once considered impossible, with a single surgical injection slowing overall disease progression by 75% and functional decline by 60% in a University College London clinical trial. The experimental treatment, AMT-130, permanently reprograms neurons to stop producing the toxic protein responsible for destroying brain cells in this fatal inherited disorder. For the roughly 41,000 Americans living with Huntington’s and 200,000 more at genetic risk, the word “stable” now carries real clinical meaning. Beyond one disease, the gene-silencing techniques validated here are accelerating research into Alzheimer’s, Parkinson’s, and other neurological conditions affecting tens of millions worldwide.

A neuroscientist reviewing brain activity data on a monitor for an article about epilepsy drug RAP-219

New epilepsy drug cuts seizures by nearly 80% in mid-stage trial

By / / Good News For Humankind

Epilepsy drug RAP-219 has shown striking results in a mid-stage clinical trial, reducing seizures by a median of 77.8% in adults whose epilepsy had not responded to existing medications. Developed by Rapport Therapeutics, the drug works by precisely targeting overactive brain regions rather than broadly suppressing electrical activity across the whole brain. Nearly one in four participants became completely seizure-free during the eight-week study. The trial’s use of implanted neurostimulation devices provided objective, real-time brain data that strengthens confidence in the findings. Phase 3 trials are expected to begin in 2026.

A rural health worker examines a patient in a Kenyan village for an article about Kenya sleeping sickness elimination

Kenya becomes the 10th African nation to eliminate sleeping sickness

By / / Good News For Humankind

Sleeping sickness elimination in Kenya has earned official World Health Organization validation, making Kenya the 10th African country to reach this public health threshold. The WHO granted formal recognition in June 2025, following Kenya’s last locally transmitted case in 2009 and zero cases since. The achievement required decades of coordinated surveillance, government commitment, and community-level action across six historically affected counties. It also marks Kenya’s second neglected tropical disease elimination win, following Guinea worm disease in 2018 — a record few low- and middle-income countries can match.

A health worker administering a vaccine to a young child for an article about Nepal rubella elimination

Nepal eliminates rubella as a public health problem, WHO confirms

By / / Good News For Humankind

Nepal rubella elimination was officially confirmed by the World Health Organization in August 2025, making the country the sixth nation in the WHO South-East Asia Region to reach this milestone. The achievement reflects more than a decade of vaccination campaigns, community outreach, and surveillance work conducted despite earthquakes, a pandemic, and significant resource constraints. Rubella poses its greatest danger during pregnancy, where infection can cause miscarriage, stillbirth, or congenital rubella syndrome — a cluster of lifelong birth defects. Nepal pushed vaccine coverage above 95% nationwide, also becoming the first country in the region to adopt an advanced laboratory surveillance system.

Plastic waste floating in a Lagos canal for an article about the Lagos plastics ban — 12 words.

Lagos bans single-use plastics in one of Africa’s most polluted cities

By / / Good News For Humankind

Lagos plastics ban took effect July 1, 2025, prohibiting styrofoam containers, plastic cutlery, plates, and straws across Nigeria’s commercial capital of 15 million people. The city generates at least 13,000 tons of waste daily, with plastic clogging canals and worsening seasonal flooding in low-income neighborhoods. The ban builds on a 2024 federal policy targeting similar items, signaling coordinated national momentum. What makes this significant is that it carries real enforcement consequences — including business closure for repeat violators — setting it apart from environmental pledges with no teeth.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

FDA approves twice-yearly lenacapavir HIV prevention shot with 99.9% effectiveness

By / / Good News For Humankind

Lenacapavir HIV prevention has reached a landmark moment: the FDA has approved the twice-yearly injectable drug — brand name Yeztugo — as the first long-acting PrEP option in history. Clinical trials showed it stopped transmission in more than 99.9% of participants, outperforming daily oral PrEP across tens of thousands of people. The breakthrough matters because adherence to daily medication has always been the weak point in HIV prevention, particularly in high-burden communities facing stigma and limited clinic access. Gilead has also signed royalty-free licensing agreements to supply affordable versions to 120 countries, prioritizing sub-Saharan Africa, Southeast Asia, and the Caribbean.

A rural health worker distributing bed nets in a Southeast Asian village for an article about Timor-Leste malaria-free certification

Timor-Leste becomes malaria-free after recording 223,000 cases in a single year

By / / Good News For Humankind

Timor-Leste has achieved malaria-free certification from the World Health Organization, eliminating a disease that once struck more than 223,000 people in a single year. The designation marks the culmination of a national malaria program launched in 2003, just one year after the country gained independence from decades of occupation and conflict. Reaching zero indigenous cases required free diagnosis and treatment, widespread bed net distribution, community health workers, and a real-time surveillance system built to catch reintroduction at borders. Timor-Leste is now only the third country in the WHO South-East Asia Region to earn this status, joining the Maldives and Sri Lanka.